229 related articles for article (PubMed ID: 25446816)
1. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma.
Ito M; Ishii G; Nagai K; Maeda R; Nakano Y; Ochiai A
Chest; 2012 Jul; 142(1):151-158. PubMed ID: 22302300
[TBL] [Abstract][Full Text] [Related]
3. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.
Neri S; Ishii G; Taira T; Hishida T; Yoshida J; Nishimura M; Nagai K; Ochiai A
Ann Surg Oncol; 2012 Nov; 19(12):3953-62. PubMed ID: 22669451
[TBL] [Abstract][Full Text] [Related]
4. Podoplanin expression in cancer-associated fibroblasts predicts unfavourable prognosis in patients with pathological stage IA lung adenocarcinoma.
Kubouchi Y; Yurugi Y; Wakahara M; Sakabe T; Haruki T; Nosaka K; Miwa K; Araki K; Taniguchi Y; Shiomi T; Nakamura H; Umekita Y
Histopathology; 2018 Feb; 72(3):490-499. PubMed ID: 28881047
[TBL] [Abstract][Full Text] [Related]
5. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
6. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Nakamura H; Ichikawa T; Nakasone S; Miyoshi T; Sugano M; Kojima M; Fujii S; Ochiai A; Kuwata T; Aokage K; Suzuki K; Tsuboi M; Ishii G
Lung Cancer; 2018 Jan; 115():56-63. PubMed ID: 29290263
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma.
Kawase A; Ishii G; Nagai K; Ito T; Nagano T; Murata Y; Hishida T; Nishimura M; Yoshida J; Suzuki K; Ochiai A
Int J Cancer; 2008 Sep; 123(5):1053-9. PubMed ID: 18546264
[TBL] [Abstract][Full Text] [Related]
8. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.
Sakai T; Aokage K; Neri S; Nakamura H; Nomura S; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Iyoda A; Tsuboi M; Ishii G
Lung Cancer; 2018 Dec; 126():64-71. PubMed ID: 30527194
[TBL] [Abstract][Full Text] [Related]
9. Relationship between stromal cells and tumor spread through air spaces in lung adenocarcinoma.
Qiu X; Chen D; Liu Y; Duan S; Zhang F; Zhang Y; Li F; Chen C; Chen Y
Thorac Cancer; 2019 Feb; 10(2):256-267. PubMed ID: 30605235
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.
Yoh K; Ishii G; Yokose T; Minegishi Y; Tsuta K; Goto K; Nishiwaki Y; Kodama T; Suga M; Ochiai A
Clin Cancer Res; 2004 Mar; 10(5):1691-7. PubMed ID: 15014021
[TBL] [Abstract][Full Text] [Related]
11. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
12. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype.
Ono S; Ishii G; Nagai K; Takuwa T; Yoshida J; Nishimura M; Hishida T; Aokage K; Fujii S; Ikeda N; Ochiai A
Chest; 2013 Apr; 143(4):963-970. PubMed ID: 23081722
[TBL] [Abstract][Full Text] [Related]
13. Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus.
Schoppmann SF; Jesch B; Riegler MF; Maroske F; Schwameis K; Jomrich G; Birner P
Clin Exp Metastasis; 2013 Apr; 30(4):441-6. PubMed ID: 23161183
[TBL] [Abstract][Full Text] [Related]
14. Ezrin-expressing lung adenocarcinoma cells and podoplanin-positive fibroblasts form a malignant microenvironment.
Suzuki S; Ishii G; Matsuwaki R; Neri S; Hashimoto H; Yamauchi C; Aokage K; Hishida T; Yoshida J; Kohno M; Nagai K; Ochiai A
J Cancer Res Clin Oncol; 2015 Mar; 141(3):475-84. PubMed ID: 25304618
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy.
Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T
Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268
[TBL] [Abstract][Full Text] [Related]
16. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma.
Yamanashi T; Nakanishi Y; Fujii G; Akishima-Fukasawa Y; Moriya Y; Kanai Y; Watanabe M; Hirohashi S
Oncology; 2009; 77(1):53-62. PubMed ID: 19556810
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
